GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo targets rare cancers left behind by progress
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot every 2 weeks could control tumor growth in gut cancers
Disease control OngoingThis phase 3 trial compares a new form of octreotide (CAM2029) given as a shot every 2 weeks to standard monthly injections in 332 people with advanced neuroendocrine tumors of the gut or pancreas. The main goal is to see if the new drug delays tumor growth better than current tr…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a liver artery shot make cancer treatment more effective?
Disease control OngoingThis early study tests whether giving the drug Lutathera directly into the liver artery is safe and practical for people with neuroendocrine tumors that have spread mainly to the liver. Ten participants will receive two doses into the liver artery followed by two standard IV dose…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Promising drug combo shows hope for slowing rare gut tumors
Disease control OngoingThis study tested whether adding Lutathera to standard octreotide treatment can delay tumor growth in people with advanced neuroendocrine tumors of the stomach, intestines, or pancreas. The trial involved 226 patients with fast-growing tumors (grades 2 and 3) who had not received…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could abemaciclib be the next weapon against Hard-to-Treat gut tumors?
Disease control OngoingThis phase 2 trial tests the drug abemaciclib (Verzenio) in 20 patients with advanced gastroenteropancreatic neuroendocrine tumors that have spread, are not responding to treatment, and cannot be surgically removed. The drug works by blocking enzymes that help cancer cells grow. …
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Radioactive drug aims to shrink Hard-to-Treat gut tumors
Disease control OngoingThis Phase 3 trial tests a radioactive drug called 177Lu-Edotreotide against standard chemotherapy for people with aggressive neuroendocrine tumors of the gut or pancreas. The drug targets tumor cells and delivers radiation directly. About 259 participants will be followed to see…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 26, 2026 16:35 UTC
-
Radioactive injection shows promise in slowing neuroendocrine tumor growth
Disease control OngoingThis Phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors that had stopped responding to treatment. The main goal was to see if the radioactive drug could de…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Double PET scan may unlock secrets of gut tumors
Knowledge-focused OngoingThis pilot study is testing whether combining two different PET scans can give doctors a clearer picture of neuroendocrine tumors (NETs) in the gut. The scans measure how tumors take up different tracers, which may reveal whether a tumor is slow-growing or aggressive. The goal is…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Lutathera safety under the microscope: 1,000+ patients monitored Long-Term
Knowledge-focused OngoingThis study follows over 1,000 adults with advanced neuroendocrine tumors who have already been treated with Lutathera. Researchers are tracking long-term side effects, including the risk of new cancers, and overall survival. The goal is to better understand the drug's safety over…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Advanced Accelerator Applications • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Massive study aims to unravel best treatments for neuroendocrine tumors
Knowledge-focused OngoingThis study follows over 2,500 people with neuroendocrine tumors (NETs) to understand their symptoms and how treatments are chosen. Participants fill out surveys about quality of life and care experiences over 18 months. Researchers will link this to medical records to find which …
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New blood test registry aims to improve neuroendocrine tumor care
Knowledge-focused ENROLLING_BY_INVITATIONThis registry is collecting blood samples and health data from 400 people with neuroendocrine tumors. The goal is to see if a new blood test called NETest can help detect tumor activity and predict disease progression. Participants include patients before and after surgery, those…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Wren Laboratories LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC